FSTX Stock Overview
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy.
F-star Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.32|
|52 Week High||US$6.76|
|52 Week Low||US$2.07|
|1 Month Change||8.79%|
|3 Month Change||-18.03%|
|1 Year Change||4.11%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||31.03%|
Recent News & Updates
F-star Therapeutics: Running Into A National Security RoadblockSep 22
F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma saleSep 15
Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) RevenuesMay 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest ResultsMar 17
These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS ForecastsMar 16
Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks LikeMar 17
|FSTX||US Biotechs||US Market|
Return vs Industry: FSTX exceeded the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: FSTX exceeded the US Market which returned -21.2% over the past year.
|FSTX Average Weekly Movement||10.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: FSTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: FSTX's weekly volatility (10%) has been stable over the past year.
About the Company
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.
F-star Therapeutics, Inc. Fundamentals Summary
|FSTX fundamental statistics|
Is FSTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FSTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.04|
|Net Profit Margin||-211.32%|
How did FSTX perform over the long term?See historical performance and comparison